Rowan Flynn, Ph.D.

As a Principal Scientist at RoslinCT, Dr. Flynn brings nearly two decades of valuable research and manufacturing expertise in the fields of gene and stem cell therapy, cultivated through experiences in both industry and academia.

In his prior role as the Head of Pluripotent Sciences at Censo Biotechnologies, he led iPSC manufacturing, gene editing, and innovation projects for biotech and pharma clients in the US and EU.

Prior to joining Censo, Dr. Flynn developed gene editing strategies for academic and industrial partners as part of the StemBANCC project at the University of Oxford where he also conducted independent research in motor neuron disease using genetically modified iPSC-derived cell models.

As a fellow at the University of Washington in Seattle, he demonstrated the efficacy of HD-Ad viral vectors in delivering therapeutic transgenes to treat cardiovascular disease and reverse atherosclerosis in large animal models and developed a cell-therapy-based strategy for the treatment of dystrophic epidermolysis bullosa using genetically modified iPSC-derived keratinocytes. Dr. Flynn holds a PhD in Molecular Physiology, an MSc in Biotechnology and a BSc in Microbiology.